Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis.


Journal

Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486

Informations de publication

Date de publication:
Mar 2021
Historique:
revised: 13 10 2020
received: 25 06 2020
accepted: 14 10 2020
pubmed: 7 11 2020
medline: 20 4 2021
entrez: 6 11 2020
Statut: ppublish

Résumé

Recently, several countries authorized the use of cannabis flowering tops (dried inflorescences) with a standardized amount of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and their acidic precursors [Δ-9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA)] to treat neurogenic pain. We studied the acute pharmacological effects and disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine of 13 healthy individuals treated with medical cannabis decoction and oil. Cannabinoids and their metabolites were quantified by ultrahigh performance tandem mass spectrometry. Even if the oil contained a significantly higher amount of THC, the absorption of THC and its metabolites were similar in both herbal preparations. Conversely, whereas oil contained a significantly higher amount of CBD and a lower amount of CBDA, absorption was significantly higher after decoction intake. Only cannabinoids present in both herbal preparations (THC, CBD, THCA-A and CBDA) were found in oral fluid, due to the higher acidity compared with that of serum. THC metabolites urinary excretion was always higher after decoction administration. Decoction induced greater feeling of hunger and drowsiness than oil preparation. Pharmacokinetics of cannabinoids, their precursors and their metabolites in biological fluids of individuals treated with cannabis decoction and oil showed a high interindividual variability. The aqueous preparation was generally better absorbed than the oil, even if it contained a minor amount of THC, THCA-A and CBD.

Identifiants

pubmed: 33155722
doi: 10.1002/ptr.6931
doi:

Substances chimiques

Cannabinoids 0
Medical Marijuana 0
Pharmaceutical Preparations 0
Plant Extracts 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1646-1657

Subventions

Organisme : Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
ID : FIS PI14/00715
Organisme : Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
ID : FIS PI17/019
Organisme : Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
ID : PFIS FI18/00179
Organisme : Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
ID : FIS PI17/01962
Organisme : AGAUR Gencat Suport Grups Recerca
ID : 2017 SGR 316
Organisme : Ministerio de Sanidad, Política Social e Igualdad (Plan Nacional Sobre Drogas-PNSD)
ID : 2015I054
Organisme : ISCIII-Plataforma de Unidades de Iinvestigación y Ensayos Clínicos-SCREN
ID : PT17/0017/0016
Organisme : ISCIII-Red de Trastornos Adictivos (RTA)
ID : RD16/0017/0003; Italian Presidence of Ministers Council, Department of Antidrug Policy

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

Baratta, F., Simiele, M., Pignata, I., Ravetto Enri, L., Torta, R., De Luca, A., … Brusa, P. (2019). Development of standard operating protocols for the optimization of cannabis-based formulations for medical purposes. Frontiers in Pharmacology, 10, 701.
Belendiuk, K. A., Baldini, L. L., & Bonn-Miller, M. O. (2015). Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addiction Science & Clinical Practice, 10, 10.
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Clauw, D. J., Goesling, J., & Williams, D. A. (2019). Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. The Journal of Pain, 20(11), 1362-1372.
Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J., & Williams, C. M. (2016). Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology (Berline), 233(2), 243-254.
Carcieri, C., Tomasello, C., Simiele, M., De Nicolò, A., Avataneo, V., Canzoneri, L., … D'Avolio, A. (2018). Cannabinoids concentration variability in cannabis olive oil galenic preparations. Journal of Pharmacy and Pharmacology, 70(1), 143-149.
Gherzi, M., Milano, G., Fucile, C., Calevo, M. G., Mancardi, M. M., Nobili, L., … De Grandis, E. (2020). Safety and pharmacokinetics of medical cannabis preparation in a monocentric series of young patients with drug resistant epilepsy. Complementary Therapies in Medicine, 51, 102402.
Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry Biodiversity, 4(8), 1770-1804.
Martin-Santos, R., Crippa, J. A., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., … McGuire, P. K. (2012). Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Current Pharmaceutical Design, 18(32), 4966-4979.
Moldzio, R., Pacher, T., Krewenka, C., Kranner, B., Novak, J., Duvigneau, J. C., & Wolf-Dieter, R. (2012). Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP(+) affected murine mesencephalic cultures. Phytomedicine, 19(8-9), 819-824.
Pacifici, R., Marchei, E., Salvatore, F., Guandalini, L., Busardò, F. P., & Pichini, S. (2017). Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 55(10), 1555-1563.
Pacifici, R., Marchei, E., Salvatore, F., Guandalini, L., Busardò, F. P., & Pichini, S. (2018). Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 56(4), 94-96.
Pacifici, R., Marchei, E., Salvatore, F., Guandalini, L., Busardò, F. P., & Pichini, S. (2019). Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 57(7), e165-e168.
Papaseit, E., Pérez-Mañá, C., de Sousa Fernandes Perna, E. B., Olesti, E., Mateus, J., Kuypers, K. P., … Farré, M. (2019). Mephedrone and alcohol interactions in humans. Frontiers in Pharmacology, 10, 1588.
Pellesi, L., Licata, M., Verri, P., Vandelli, D., Palazzoli, F., Marchesi, F., … Guerzoni, S. (2018). Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study. European Journal of Clinical Pharmacology, 74(11), 1427-1436.
Peters, F. T., Wissenbach, D. K., Busardò, F. P., Marchei, E., & Pichini, S. (2017). Method development in forensic toxicology. Current Pharmaceutical Design, 23(36), 5455-5467.
Pichini, S., Mannocchi, G., Gottardi, M., Pérez-Acevedo, A. P., Poyatos, L., Papaseit, E., … Busardò, F. P. (2020). Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. Talanta, 209, 120537.
Rock, E. M., Kopstick, R. L., Limebeer, C. L., & Parker, L. A. (2013). Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. British Journal of Pharmacology, 170(3), 641-648.
Ruhaak, L. R., Felth, J., Karlsson, P. C., Rafter, J. J., Verpoorte, R., & Bohlin, L. (2011). Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biological and Pharmaceutical Bulletin, 34(5), 774-778.
Russo, E. B., & McPartland, J. M. (2003). Cannabis is more than simply Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berline), 165(4), 431-432.
Takeda, S., Okazaki, H., Ikeda, E., Abe, S., Yoshioka, Y., Watanabe, K., & Aramaki, H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. The Journal of Toxicological Sciences, 39(5), 711-716.
Wille, S. M. R., Coucke, W., De Baere, T., & Peters, F. T. (2017). Update of standard practices for new method validation in forensic toxicology. Current Pharmaceutical Design, 23(36), 5442-5454.

Auteurs

Ana P Pérez-Acevedo (AP)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Roberta Pacifici (R)

National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.

Giulio Mannocchi (G)

School of Law, University of Camerino, Camerino, Italy.

Massimo Gottardi (M)

Comedical S.rL, Trento, Italy.

Lourdes Poyatos (L)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Esther Papaseit (E)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Clara Pérez-Mañá (C)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Soraya Martin (S)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Francesco P Busardò (FP)

Department of Excellence - Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy.

Simona Pichini (S)

National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.

Magí Farré (M)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH